丙戍酸镁缓释片合并维思通对精神分裂症患者脂代谢影响

Effect of Lipid Metabolism in Patients with Schizophrenia by Using Magnesium Valproate Combined with Risperidone

目的分析丙戍酸镁合并维思通治疗对精神分裂症患者脂代谢的影响。方法 200例女性首发精神分裂症患者随机分为研究组与对照组各100例,研究组丙戍酸镁合并维思通治疗,对照组维思通治疗。于治疗前,治疗2、4、6、8、12周采集血样,检测胆固醇(TC)进行比较。结果研究组治疗各周后胆固醇与治疗前相比脂代谢无明显变化。对照组自第2周即出现明显升高,此后各周持续升高(t=2.23,6.69,11.81,14.74,36.39;P<0.01),两组各周比较有显著差异(t=2.74,6.68,11.19,13.82,28.65;P<0.01)。结论丙戍酸镁合并维思通治疗对精神分裂症患者脂代谢影响小,与丙戍酸镁特殊作用机制有关。

Objective To explore the difference of lipid metabolism in patients with schizophrenia by using magnesium valproate combined with risperidone. Methods A total of 200 female first-episode schizophrenic patients were randomly divided into study group and control group. The study group were cured by magnesium valproate combined with risperidone, and the control group only by risperi- done. To collect blood sample for testing TC and GABA at the start of treatment and 2,4,6,8,12 weeks. Results There were no obvious changes in TC in study group compared with before treatment, it rised obviously at 2 weeks and continued to rise since 2 weeks （ t = 2. 2.3, 6. 69,11.81,14. 74,36. 39 ; P 〈 0.01 ） in control group, there were significant differences in two groups each week （ t = 2. 74,6. 68, 11.19,13.82,28.65 ;P 〈 0. 01 ）. Conclusion It has very small influence of lipid metabolism in schizophrenic patients to use magnesium valproate combined with risperidone, the reason could be related to special function mechanism of magnesium valproate.